🧪 New online today! Anti-ST2 antibody reduces airway hyperresponsiveness mediated by monocyte-derived #macrophages during #influenza A infection www.mucosalimmunology.org/article/S193...
Anti-ST2 antibody reduces airway hyperresponsiveness mediated by monocyte-derived macrophages during influenza A infection
Influenza A virus (IAV) infections trigger asthma attacks and cause airway hyperresponsiveness
(AHR) in murine models. However, the mechanism by which AHR is induced remains to
be fully elucidated. He...
www.mucosalimmunology.org
May 7, 2025 at 2:41 PM
🧪 New online today! Anti-ST2 antibody reduces airway hyperresponsiveness mediated by monocyte-derived #macrophages during #influenza A infection www.mucosalimmunology.org/article/S193...
I can't decide whether I like or hate this new nomenclature.
October 9, 2025 at 9:06 AM
I can't decide whether I like or hate this new nomenclature.
The "No" campaign financed by Larry Stone and Gerry Dicker was the third largest anti-transit election campaign in state history.
On a opposition campaign dollar per NO vote:
ST2: $0.28
ST3: $1.11
Yes for Buses is trending over $5 per NO vote...
On a opposition campaign dollar per NO vote:
ST2: $0.28
ST3: $1.11
Yes for Buses is trending over $5 per NO vote...
August 7, 2026 at 4:28 PM
The "No" campaign financed by Larry Stone and Gerry Dicker was the third largest anti-transit election campaign in state history.
On a opposition campaign dollar per NO vote:
ST2: $0.28
ST3: $1.11
Yes for Buses is trending over $5 per NO vote...
On a opposition campaign dollar per NO vote:
ST2: $0.28
ST3: $1.11
Yes for Buses is trending over $5 per NO vote...
Mabwell's Groundbreaking Anti-ST2 Monoclonal Antibody 9MW1911 Receives FDA IND Clearance for COPD Study#China#Shanghai#Mabwell #9MW1911#anti-ST2
Mabwell's Groundbreaking Anti-ST2 Monoclonal Antibody 9MW1911 Receives FDA IND Clearance for COPD Study
Mabwell has obtained FDA IND clearance for its innovative anti-ST2 monoclonal antibody 9MW1911, set to enter Phase IIa clinical trials for COPD.
third-news.com
December 24, 2025 at 2:13 PM
'Tumor debris phagocytosis by MSMs induces the cytokine IL-33, and blocking the IL-33 receptor (ST2) or deletion of Il33 in MSMs enhances therapy responses. Mechanistically, IL-33 activates T regulatory cells in TDLNs that migrate to the tumor to suppress CD8+ T cells.'
#Immunology #Immunotherapy
#Immunology #Immunotherapy
Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33
Although immunity is an important component of cancer therapy responses, suppressive
immune feedback restricting anti-tumor activity has not been extensively examined.
In this issue of Cancer Cell, La...
www.cell.com
March 7, 2025 at 10:29 AM
'Tumor debris phagocytosis by MSMs induces the cytokine IL-33, and blocking the IL-33 receptor (ST2) or deletion of Il33 in MSMs enhances therapy responses. Mechanistically, IL-33 activates T regulatory cells in TDLNs that migrate to the tumor to suppress CD8+ T cells.'
#Immunology #Immunotherapy
#Immunology #Immunotherapy
Anticuerpo monoclonal anti-ST2 disminuye las exacerbaciones en pacientes exfumadores con EPOC moderada a grave firstwordpharma.com/story/6718512
firstwordpharma.com
December 4, 2025 at 7:04 AM
Anticuerpo monoclonal anti-ST2 disminuye las exacerbaciones en pacientes exfumadores con EPOC moderada a grave firstwordpharma.com/story/6718512
Astegolimab for COPD with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials
doi.org/10.1093/ajrc... @atscommunity.bsky.social
doi.org/10.1093/ajrc... @atscommunity.bsky.social
Astegolimab for chronic obstructive pulmonary disease with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials
AbstractRationale. The efficacy and safety of astegolimab, an anti-ST2 monoclonal antibody, was evaluated in participants with chronic obstructive pulmonar
doi.org
September 18, 2026 at 2:55 PM
Astegolimab for COPD with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials
doi.org/10.1093/ajrc... @atscommunity.bsky.social
doi.org/10.1093/ajrc... @atscommunity.bsky.social
RRIDs were included in this paper. Thanks for making your methods matter! #reproducibility #STMpublishing #methodsmatter
IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer
doi.org
October 22, 2025 at 7:00 AM
RRIDs were included in this paper. Thanks for making your methods matter! #reproducibility #STMpublishing #methodsmatter
I've never seen ST2, but the first film is brilliant, since it completely flips the meathead politics of the Heinlein book by satire and turns it into a really clever piece of anti militaristic, anti propaganda filmmaking
December 16, 2024 at 6:14 PM
I've never seen ST2, but the first film is brilliant, since it completely flips the meathead politics of the Heinlein book by satire and turns it into a really clever piece of anti militaristic, anti propaganda filmmaking
Novel Biologic Gets Narrow Win for Preventing COPD Flare-ups www.medpagetoday.com/meetingcover...
Novel Biologic Gets Narrow Win for Preventing COPD Flare-ups
Mixed results with anti-ST2 monoclonal antibody astegolimab in pivotal trials
www.medpagetoday.com
September 29, 2025 at 12:48 PM
Novel Biologic Gets Narrow Win for Preventing COPD Flare-ups www.medpagetoday.com/meetingcover...
In @nature, Liao et al showed this commensal promotes type-2 immunity in the gut via IL-33/ST2, influencing protective anti-helminth responses and food allergy models.
November 27, 2024 at 10:13 PM
In @nature, Liao et al showed this commensal promotes type-2 immunity in the gut via IL-33/ST2, influencing protective anti-helminth responses and food allergy models.
Mabwell Reports Significant Reduction in COPD Exacerbations with 9MW1911 Antibody in Phase IIa Study#China#Shanghai#Mabwell#COPD #9MW1911
Mabwell Reports Significant Reduction in COPD Exacerbations with 9MW1911 Antibody in Phase IIa Study
Mabwell has reported promising Phase IIa results showing over 40% reduction in severe COPD exacerbations with their anti-ST2 antibody 9MW1911. This breakthrough could revolutionize treatment.
third-news.com
December 1, 2025 at 2:32 PM
Leishmania inhibits NLRP3 expression through IL-33/ST2 signaling driven SOCS1-mediated p65 degradation PubMed
Leishmania inhibits NLRP3 expression through IL-33/ST2 signaling driven SOCS1-mediated p65 degradation
The dynamic interplay between pro- and anti-inflammatory cytokines plays a crucial role in regulating host immune responses. In our earlier study, we showed that Leishmania donovani-induced IL-33 destabilizes host cytokine dynamics by downregulating TNF-α and IL-12 and ensures intramacrophage parasite survival. Another pertinent host favorable proinflammatory cytokine is Il-1β, maturation of which depends on the activation of NLRP3 inflammasome complex. Our present study highlights that...
dlvr.it
September 16, 2026 at 10:54 PM
Leishmania inhibits NLRP3 expression through IL-33/ST2 signaling driven SOCS1-mediated p65 degradation PubMed
Mabwell Showcases Promising Phase Ib/IIa Results of 9MW1911 for COPD at ERS 2026#China#Shanghai#Mabwell#COPD #9MW1911
Mabwell Showcases Promising Phase Ib/IIa Results of 9MW1911 for COPD at ERS 2026
Mabwell presents Phase Ib/IIa clinical data on its anti-ST2 monoclonal antibody 9MW1911 for COPD patients, demonstrating significant efficacy in reducing exacerbations.
third-news.com
September 4, 2026 at 1:09 PM
#Roche has posted a mixed set of data from two clinical trials of its anti-IL-33/ST2 antibody astegolimab in chronic obstructive pulmonary disease (#COPD), casting a shadow over the programme.
pharmaphorum.com/news/roches-...
pharmaphorum.com/news/roches-...
July 21, 2025 at 10:51 AM
#Roche has posted a mixed set of data from two clinical trials of its anti-IL-33/ST2 antibody astegolimab in chronic obstructive pulmonary disease (#COPD), casting a shadow over the programme.
pharmaphorum.com/news/roches-...
pharmaphorum.com/news/roches-...
Feed: "Business-News-Today.com"
By: Srinath on Thursday, December 25, 2025
By: Srinath on Thursday, December 25, 2025
Mabwell’s anti-ST2 antibody enters U.S. trials: Can 9MW1911 reshape immunotherapy for COPD?
Mabwell’s anti-ST2 antibody 9MW1911 enters U.S. trials after strong COPD data in China. Find out what this could mean for immunotherapy's future in COPD.
business-news-today.com
December 26, 2025 at 5:24 AM
Feed: "Business-News-Today.com"
By: Srinath on Thursday, December 25, 2025
By: Srinath on Thursday, December 25, 2025
IL-33 induces high levels of the interleukin-1 receptor antagonist (IL-1Ra) in ST2+ Treg cells. This reduces the activity of neutrophils and gd T cells as well as ILCs. This can prevent immunopathology, but also dampens the anti-influenza response.
3/7
3/7
November 10, 2023 at 8:56 AM
IL-33 induces high levels of the interleukin-1 receptor antagonist (IL-1Ra) in ST2+ Treg cells. This reduces the activity of neutrophils and gd T cells as well as ILCs. This can prevent immunopathology, but also dampens the anti-influenza response.
3/7
3/7
Novel Biologic Gets Narrow Win for Preventing COPD Flare-ups
(MedPage Today) -- Novel anti-ST2 monoclonal antibody astegolimab modestly reduced chronic obstructive pulmonary disease (COPD) exacerbations in the phase IIb ALIENTO trial. The biologic dosed every 2 weeks reduced moderate or severe…
(MedPage Today) -- Novel anti-ST2 monoclonal antibody astegolimab modestly reduced chronic obstructive pulmonary disease (COPD) exacerbations in the phase IIb ALIENTO trial. The biologic dosed every 2 weeks reduced moderate or severe…
Novel Biologic Gets Narrow Win for Preventing COPD Flare-ups
(MedPage Today) -- Novel anti-ST2 monoclonal antibody astegolimab modestly reduced chronic obstructive pulmonary disease (COPD) exacerbations in the phase IIb ALIENTO trial. The biologic dosed every 2 weeks reduced moderate or severe COPD exacerbations... Source link
n24usa.com
September 28, 2025 at 10:55 PM
Novel Biologic Gets Narrow Win for Preventing COPD Flare-ups
(MedPage Today) -- Novel anti-ST2 monoclonal antibody astegolimab modestly reduced chronic obstructive pulmonary disease (COPD) exacerbations in the phase IIb ALIENTO trial. The biologic dosed every 2 weeks reduced moderate or severe…
(MedPage Today) -- Novel anti-ST2 monoclonal antibody astegolimab modestly reduced chronic obstructive pulmonary disease (COPD) exacerbations in the phase IIb ALIENTO trial. The biologic dosed every 2 weeks reduced moderate or severe…
Decitabine co-operates with the IL-33/ST2 axis modifying the tumor microenvironment and improving the response to PD-1 blockade in melanoma
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Decitabine co-operates with the IL-33/ST2 axis modifying the tumor microenvironment and improving the response to PD-1 blockade in melanoma - Journal of Experimental & Clinical Cancer Research
Background IL-33 is an epithelial-derived alarmin with various roles in cancer. In melanoma, endogenous and exogenous IL-33 exert anti-tumor effects through the stimulation of several immune effector ...
link.springer.com
May 22, 2025 at 4:40 PM
Decitabine co-operates with the IL-33/ST2 axis modifying the tumor microenvironment and improving the response to PD-1 blockade in melanoma
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Astegolimab, anticuerpo anti-ST2, reduce las exacerbaciones en pacientes con EPOC fumadores y exfumadores con exacerbaciones frecuentes independiente de la cuenta eosinofílica firstwordpharma.com/story/5982465
firstwordpharma.com
July 21, 2025 at 2:42 PM
Astegolimab, anticuerpo anti-ST2, reduce las exacerbaciones en pacientes con EPOC fumadores y exfumadores con exacerbaciones frecuentes independiente de la cuenta eosinofílica firstwordpharma.com/story/5982465
Novel anti-ST2 monoclonal antibody astegolimab modestly reduced chronic obstructive pulmonary disease exacerbations in the phase IIb ALIENTO trial. #ERSCongress
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
Novel Biologic Gets Narrow Win for Preventing COPD Flare-ups
Mixed results with anti-ST2 monoclonal antibody astegolimab in pivotal trials
www.medpagetoday.com
September 30, 2025 at 2:09 PM
Novel anti-ST2 monoclonal antibody astegolimab modestly reduced chronic obstructive pulmonary disease exacerbations in the phase IIb ALIENTO trial. #ERSCongress
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
Thoughts on this? >> Roche's COPD drug flunks phase 3 trial, denting hopes of
approval this year >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #healthcare #pharmaceutical #biotech
approval this year >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #healthcare #pharmaceutical #biotech
Roche's COPD drug flunks phase 3 trial, denting hopes of
approval this year
Roche’s hopes of getting astegolimab to regulators this year have taken a hit after the anti-ST2 monoclonal antibody failed to reduce flare-ups in a phase 3 study.
dlvr.it
July 21, 2025 at 11:31 AM
Thoughts on this? >> Roche's COPD drug flunks phase 3 trial, denting hopes of
approval this year >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #healthcare #pharmaceutical #biotech
approval this year >> Comment below! #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #healthcare #pharmaceutical #biotech